Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label study of M9466 with carboplatin-based therapy in advanced solid tumors and extensive-stage small cell lung cancer
jRCT2031240640Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of M9466, carboplatin, etoposide and atezolizumab in Nonhematologic neoplasms and small cell lung cancer (SCLC) (3 arms), sponsored by Merck KGaA. Primary endpoints: Occurrence of TEAEs and treatment-related adverse events and Occurrence of dose-limiting toxicities. Started Feb 2025; status: completed.
02
Drugs
M9466carboplatinetoposideatezolizumab
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031240640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240640.